Physician profile
Ralph Boccia
NPI 1881663284
$3,139,728.06
in general payments reported to CMS, 2019-2025
100 companies · $244K in 2025
The $244K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $707K · 2020: $452K · 2021: $394K · 2022: $493K · 2023: $416K · 2024: $434K · 2025: $244K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $516K · Consulting Fee: $334K · Travel and Lodging: $111K · Honoraria: $94K · Food and Beverage: $34K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,500 · Education: $15.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $515,542.00 |
| Consulting Fee | $334,306.18 |
| Travel and Lodging | $110,757.95 |
| Honoraria | $94,003.00 |
| Food and Beverage | $34,418.13 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,500.00 |
| Education | $15.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $300,462.93 | 2019-2025 | Opdivo, Reblozyl, Augtyro |
| Abbvie INC. | $213,968.07 | 2019-2025 | Venclexta, Epkinly |
| Janssen Biotech, INC. | $210,114.56 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Celgene Corporation | $175,063.64 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $166,383.39 | 2019-2025 | Nplate, Imdelltra (Amg757), Kyprolis |
| Astrazeneca Pharmaceuticals Lp | $163,093.17 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Fennec Pharmaceuticals, INC. | $156,503.90 | 2024-2025 | Pedmark, Fyarro |
| Beigene USA, INC. | $139,518.74 | 2020-2025 | Brukinsa, Tevimbra |
| Genzyme Corporation | $136,300.53 | 2019-2025 | |
| Sobi, INC | $134,863.68 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $131,455.22 | 2019-2025 | Libtayo |
| Daiichi Sankyo INC. | $121,903.88 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $109,248.95 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Rigel Pharmaceuticals, INC. | $102,571.11 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacosmos Therapeutics INC. | $102,198.43 | 2020-2025 | Monoferric |
Show all 99 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $72,264.49 | 2020-2025 | Xpovio |
| G1 Therapeutics, INC. | $69,405.01 | 2021-2023 | Cosela |
| Genmab U.S., INC. | $63,387.81 | 2023-2025 | Epkinly |
| Dova Pharmaceuticals | $54,384.27 | 2019-2021 | |
| Taiho Oncology, INC. | $46,568.70 | 2019-2025 | |
| Coherus Oncology, INC. | $37,464.99 | 2020-2023 | |
| Puma Biotechnology, INC. | $34,462.38 | 2019-2025 | |
| Seagen INC. | $33,986.68 | 2019-2023 | Tukysa, Padcev, Tivdak |
| Aadi Bioscience, INC. | $33,500.00 | 2025 | Fyarro |
| Secura Bio, INC. | $33,467.12 | 2019-2024 | Copiktra |
| Genentech USA, INC. | $32,522.94 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Epizyme, INC. | $24,504.36 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23,097.70 | 2019-2025 | Fruzaqla, Hyqvia, Ninlaro |
| Jazz Pharmaceuticals INC. | $21,574.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $19,693.59 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Stemline Therapeutics INC. | $15,807.75 | 2021-2025 | Orserdu |
| Beone Medicines USA, INC. | $14,943.01 | 2025 | Brukinsa, Tevimbra |
| Lilly USA, LLC | $14,058.07 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Blueprint Medicines Corporation | $12,875.67 | 2020-2024 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $12,004.36 | 2020-2025 | Tazverik, Onivyde, Somatuline Depot |
| American Regent | $11,902.01 | 2019 | |
| Mirati Therapeutics, INC. | $10,051.30 | 2023-2024 | Krazati |
| Veracyte, INC. | $9,750.00 | 2021 | |
| Pfizer INC. | $8,809.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $8,246.95 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $5,738.58 | 2019-2025 | |
| Adc Therapeutics America, INC. | $5,130.74 | 2021-2023 | |
| Cti Biopharma Corp. | $5,003.89 | 2022-2023 | Vonjo |
| Novocure INC. | $4,903.01 | 2024-2025 | Optune Lua (Novottf-200t) |
| Grifols Shared Services North America, INC. | $4,210.00 | 2020 | |
| Ucb Sa | $4,140.00 | 2021 | |
| Geron Corporation | $3,948.84 | 2025 | Rytelo |
| Kite Pharma, INC. | $2,464.01 | 2020-2025 | Yescarta |
| Janssen Global Services, LLC | $2,294.80 | 2019-2023 | Erleada |
| Janssen Scientific Affairs, LLC | $2,140.27 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $1,424.82 | 2019-2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $1,334.15 | 2019-2025 | |
| Partner Therapeutics, INC. | $1,328.80 | 2019 | |
| Merck Sharp & Dohme LLC | $1,213.73 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Verastem, INC. | $1,098.39 | 2019-2020 | |
| Emd Serono, INC. | $978.87 | 2019-2025 | Bavencio |
| Acceleron Pharma, INC. | $886.57 | 2021 | |
| Eisai INC. | $694.08 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $546.23 | 2019-2025 | |
| Astellas Pharma US INC | $481.27 | 2019-2024 | Padcev, Xtandi |
| Gilead Sciences, INC. | $475.68 | 2019-2025 | Trodelvy, Yescarta |
| Morphosys, US INC. | $438.36 | 2021-2023 | Monjuvi |
| Exelixis INC. | $433.52 | 2019-2025 | Cabometyx |
| Pharmaessentia USA Corporation | $433.26 | 2022-2025 | Besremi |
| Asd Specialty Healthcare, LLC | $389.02 | 2019-2020 | |
| Array Biopharma INC | $298.58 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Genentech, INC. | $252.94 | 2021-2023 | Columvi, Lunsumio |
| Myriad Genetic Laboratories, INC. | $246.43 | 2021-2025 | Myrisk, Precisetumor, Mychoice Cdx |
| Heron Therapeutics, INC. | $231.17 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $203.09 | 2021-2025 | Fotivda |
| Sumitomo Pharma America, INC. | $197.55 | 2023-2025 | Orgovyx |
| Global Blood Therapeutics, INC. | $181.10 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.90 | 2019-2025 | |
| Tg Therapeutics, INC. | $177.58 | 2021 | |
| Dendreon Pharmaceuticals LLC | $176.95 | 2020-2024 | Provenge |
| Caris Mpi, INC. | $159.19 | 2025 | Mi Cancer Seek |
| Spectrum Pharmaceuticals INC. | $157.81 | 2019-2023 | Rolvedon |
| Servier Pharmaceuticals LLC | $150.04 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $147.68 | 2019-2025 | Ultomiris |
| Adaptive Biotechnologies Corporation | $137.13 | 2022-2025 | Clonoseq |
| Eusa Pharma (US) LLC | $137.10 | 2019-2022 | |
| Eli Lilly and Company | $132.26 | 2024 | Jaypirca |
| Legend Biotech USA INC. | $131.47 | 2025 | Carvykti |
| Myovant Sciences INC. | $130.16 | 2021-2022 | |
| Accord Healthcare, INC. | $124.19 | 2024 | |
| Acrotech Biopharma INC. | $116.21 | 2021-2025 | Beleodaq, Ryzneuta |
| Deciphera Pharmaceuticals INC. | $111.46 | 2021-2025 | Qinlock, Romvimza |
| Tempus Ai, INC | $86.42 | 2024-2025 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $82.52 | 2025 | |
| Ge Healthcare | $81.57 | 2022 | |
| Janssen Research & Development, LLC | $80.00 | 2025 | Darzalex, Tecvayli |
| Eagle Pharmaceuticals, INC. | $79.44 | 2023 | |
| Clovis Oncology, INC. | $79.10 | 2019-2021 | |
| Agios Pharmaceuticals, INC. | $74.43 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $73.30 | 2022-2024 | Empaveli |
| Johnson & Johnson Health Care Systems INC. | $72.20 | 2020 | |
| Tersera Therapeutics LLC | $69.40 | 2022-2024 | Xermelo |
| Regeneron Pharmaceuticals, INC. | $66.44 | 2022 | |
| Foundation Medicine, INC. | $63.82 | 2019-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,217.85 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Boccia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.